Tiny, wireless antennas use light to monitor cellular communication
As part of a high-resolution biosensing device without wires, the antennas could help researchers decode intricate electrical signals sent by cells.
As part of a high-resolution biosensing device without wires, the antennas could help researchers decode intricate electrical signals sent by cells.
Chronic diseases like diabetes are prevalent, costly, and challenging to treat. A common denominator driving them may be a promising new therapeutic target.
By examining antigen architectures, MIT researchers built a therapeutic cancer vaccine that may improve tumor response to immune checkpoint blockade treatments.
New research reveals what it takes for a protein that is best known for protecting cells against death to take on the opposite role.
The findings suggest that biochemical and physical effects of exercise could help heal nerves.
By sidestepping the need for costly interventions, a new method could potentially reveal gene regulatory programs, paving the way for targeted treatments.
By snugly wrapping around neurons, these devices could help scientists probe subcellular regions of the brain, and might even help restore some brain function.
SMART researchers find mesenchymal stromal cells are an attractive alternative to current costly, time-intensive treatments.
Novel method to scale phenotypic drug screening drastically reduces the number of input samples, costs, and labor required to execute a screen.
A research scientist and internationally recognized authority in the field of blood cell development reflects on 45 years at MIT.
MIT scientists’ discovery yields a potent immune response, could be used to develop a potential tumor vaccine.
A chip the size of a pack of cards uses fewer resources and a smaller footprint than existing automated manufacturing platforms and could lead to more affordable cell therapy manufacturing.
New findings could help engineers design materials for light and heat management.
An atlas of human protein kinases enables scientists to map cell signaling pathways with unprecedented speed and detail.
Immunai’s founders were researchers at MIT when they launched their company to help predict how patients will respond to new treatments.